logo BDSP

Base documentaire


  1. The cost effectiveness of strategies for the treatment of intestinal parasites in immigrants.

    Article - En anglais

    Background Currently, more than 600,000 immigrants enter the United States each year from countries where intestinal parasites are endemic.

    At entry persons with parasitic infections may be asymptomatic, and stool examinations are not a sensitive method of screening for parasitosis.

    Albendazole is a new, broad-spectrum antiparasitic drug, which was approved recently by the Food and Drug Administration.

    International trials have shown albendazole to be safe and effective in eradicating many parasites.

    In the United States there is now disagreement about whether to screen all immigrants for parasites, treat all immigrants presumptively, or do nothing unless they have symptoms.

    Methods We compared the costs and benefits of no preventive intervention (watchful waiting) with those of universal screening or presumptive treatment with 400 mg of albendazole per day for five days.

    Those at risk were defined as immigrants to the United States from Asia, the Middle East, subSaharan Africa, Eastern Europe, and Latin America and the Caribbean.

    Cost effectiveness was expressed both in terms of the cost of treatment per disability-adjusted life-year (DALY) averted (one DALY is defined as the loss of one year of healthy life to disease) and in terms of the cost per hospitalization averted. (...)

    Mots-clés Pascal : Parasitose, Infection, Intestin, Immigrant, Albendazole, Antiparasitaire, Chimiothérapie, Traitement, Dépistage, Etude comparative, Analyse avantage coût, Surveillance, Etats Unis, Amérique du Nord, Amérique, Homme, Benzimidazole dérivé, Intestin pathologie, Appareil digestif pathologie

    Mots-clés Pascal anglais : Parasitosis, Infection, Gut, Immigrant, Albendazole, Parasiticid, Chemotherapy, Treatment, Medical screening, Comparative study, Cost benefit analysis, Surveillance, United States, North America, America, Human, Benzimidazole derivatives, Intestinal disease, Digestive diseases

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0173148

    Code Inist : 002B30A03B. Création : 16/11/1999.